Evidence map›Paper›PMID 42458547›Full record

ArticleJournal of nanobiotechnology2026

Dual-targeting oral nanoparticle mucosal vaccine against brucella infection: co-targeting M cells and dendritic cells.

Tingting Tian, Xinxin Qi, Juan Shi, Kaiyu Shang, Huidong Shi, Jiarui Luo, ZhengLong Chai, Chuang Li, Jianbing Ding, Yuejie Zhu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tingting TianState Key Laboratory of Pathogenesis, Prevention and Treatment of High-Incidence Diseases in Central Asia, Graduate School, Clinical Laboratory Diagnostics, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, China.
Xinxin QiDepartment of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, China.
Juan ShiState Key Laboratory of Pathogenesis, Prevention and Treatment of High-Incidence Diseases in Central Asia, Graduate School, Clinical Laboratory Diagnostics, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, China.
Kaiyu ShangState Key Laboratory of Pathogenesis, Prevention and Treatment of High-Incidence Diseases in Central Asia, Graduate School, Clinical Laboratory Diagnostics, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, China.
Huidong ShiState Key Laboratory of Pathogenesis, Prevention and Treatment of High-Incidence Diseases in Central Asia, Graduate School, Clinical Laboratory Diagnostics, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, China.
Jiarui LuoState Key Laboratory of Pathogenesis, Prevention and Treatment of High-Incidence Diseases in Central Asia, Graduate School, Clinical Laboratory Diagnostics, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, China.
ZhengLong ChaiState Key Laboratory of Pathogenesis, Prevention and Treatment of High-Incidence Diseases in Central Asia, Graduate School, Clinical Laboratory Diagnostics, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, China.
Chuang LiState Key Laboratory of Pathogenesis, Prevention and Treatment of High-Incidence Diseases in Central Asia, Graduate School, Clinical Laboratory Diagnostics, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, China.
Jianbing DingState Key Laboratory of Pathogenesis, Prevention and Treatment of High-Incidence Diseases in Central Asia, Graduate School, Clinical Laboratory Diagnostics, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, China.
Yuejie ZhuReproductive Fertility Assistance Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, China. zhuyuejie@xjmu.edu.cn.
Fengbo ZhangState Key Laboratory of Pathogenesis, Prevention and Treatment of High-Incidence Diseases in Central Asia, Graduate School, Clinical Laboratory Diagnostics, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, China. zfb131@163.com.ORCID https://orcid.org/0000-0001-5795-8672

Funding

the Central Government Guides Local Science and Technology Development Fund Project ZYYD2025ZY19the Natural Science Foundation of China 82360394the Natural Science Foundation of China 82460399the Outstanding Youth Project of the Autonomous Region No.2023D01E12the Youth Science and Technology Top Talent Project No.2022TSYCCX0112
6 · The paper itself

Abstract

This study designed and evaluated a chitosan nanoparticle-based mucosal vaccine (CS-CKS9-MEV-DCpep-NPs) targeting M cells and dendritic cells against Brucella. From four immunogenic outer membrane proteins (OMP10, Omp25, Omp31, BtpB), 41 specific epitope peptides were screened and optimized via bioinformatics and ELISPOT for high antigenicity and safety. The dual-targeting strategy uses CKS9 to enhance M cell-mediated antigen uptake and DCpep, together with CS-NPs, to activate DCs and promote their maturation. This coordinates cDC1, cDC2, and pDC subsets, inducing CD8⁺ and CD4⁺ T cell responses and strengthening Th1-biased immunity against intracellular bacteria. The vaccine activates mucosal (sIgA), humoral (IL-21, memory B cells), and cellular (Th1/CTL, central memory T cells) immunity. It significantly reduces bacterial load and tissue damage, offering comprehensive protection. Compared with conventional vaccines, this oral nanovaccine provides high safety, precise targeting, and multi-dimensional immune activation, representing a novel strategy for brucellosis control.

Indexed as

BrucellaBrucella VaccineBrucellosisDendritic CellsM CellsNanoparticlesAdministration, OralAnimalsBacterial Outer Membrane ProteinsChitosanFemaleImmunity, MucosalMiceMice, Inbred BALB CNanovaccinesProtein Subunit VaccinesBacterial Outer Membrane ProteinsBrucella VaccineChitosanNanovaccinesProtein Subunit VaccinesBrucellaChitosan nanoparticlesDendritic cellMicrofolded cellsMucosal vaccine

Identifiers

PMID42458547
PMCPMC13647541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.